Photo from wikipedia
Key Points Question How has the treatment rate for hepatitis C virus infection with direct-acting antivirals (DAAs) changed over time? Findings In this cohort study of 20 277 patients with viremic… Click to show full abstract
Key Points Question How has the treatment rate for hepatitis C virus infection with direct-acting antivirals (DAAs) changed over time? Findings In this cohort study of 20 277 patients with viremic hepatitis C and private health insurance in the United States, as of 2020, there was a suboptimal DAA treatment rate of 65.2% and a declining treatment rate beginning in 2019. Patients with hepatocellular carcinoma and decompensated cirrhosis were 30% less likely to receive DAA treatment than those without either condition. Meaning These findings suggest that DAA treatment remains underutilized, as only 2 of 3 patients eligible received treatment.
Journal Title: JAMA Network Open
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!